Maynard Um
-
-
-
-
-
-
-
FDA greenlights continued generic access for Micardis
-
-
-
-
-
-
-
Viatris (VTRS) PT Raised to $12 at BofA Securities
-
-
-
-
-
-
-
Argus Upgrades Viatris (VTRS) to Buy
-
-
-
-
-
-
-
Viatris receives FDA approval for first generic iron sucrose injection
-
-
-
-
-
-
-
VTRS Investors Have the Opportunity to Lead the Viatris Securities Fraud Lawsuit with Faruqi & Faruqi, LLP
-
-
-
-
-
-
-
VTRS FINAL DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Viatris Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important June 3 Deadline in Securities Class Action - V
-
-
-
-
-
-
-
VTRS DEADLINE NOTICE: ROSEN, A LEADING LAW FIRM, Encourages Viatris Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important June 3 Deadline in Securities Class Action - VTRS
-
422,958 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

